Analyst Price Targets — GERN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 27, 2025 10:13 am | Peter Lawson | Barclays | $4.00 | $1.61 | TheFly | Geron price target lowered to $4 from $9 at Barclays |
| November 5, 2024 11:02 am | Emily Bodnar | H.C. Wainwright | $8.00 | $4.24 | StreetInsider | H.C. Wainwright Starts Geron Corporation (GERN) at Buy |
| October 22, 2024 6:52 am | Kalpit Patel | B.Riley Financial | $5.50 | $3.95 | StreetInsider | B.Riley Reiterates Buy Rating on Geron Corporation (GERN) ahead of Q3 |
| September 9, 2024 6:23 am | Faisal Khurshid | Leerink Partners | $7.00 | $4.25 | TheFly | Geron initiated with an Outperform at Leerink |
| June 10, 2024 11:59 am | Corinne Jenkins | Goldman Sachs | $6.00 | $4.95 | StreetInsider | Geron Corporation (GERN) PT Raised to $6 at Goldman Sachs |
| June 10, 2024 6:39 am | Stephen Willey | Stifel Nicolaus | $7.00 | $4.59 | TheFly | Geron price target raised to $7 from $6 at Stifel |
| April 30, 2024 2:33 am | Joel Beatty | Robert W. Baird | $4.50 | $4.14 | StreetInsider | Baird Downgrades Geron Corporation (GERN) to Neutral 'on Valuation Concerns' |
| March 15, 2024 7:12 am | Gil Blum | Needham | $5.00 | $3.36 | StreetInsider | Geron Corporation (GERN) PT Raised to $5 at Needham, 'anticipate imetelstat will receive the go-ahead on or prior to its June 16 PDUFA date' |
| March 15, 2024 3:51 am | Corinne Jenkins | Goldman Sachs | $5.00 | $3.36 | StreetInsider | Geron Corporation (GERN) PT Raised to $5 at Goldman Sachs |
| January 9, 2023 10:30 am | — | Needham | $4.00 | $2.79 | Benzinga | Needham Maintains Buy on Geron, Raises Price Target to $4 |
Latest News for GERN
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) breached their fiduciary duties to shareholders.
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences:
ADAR1 Capital Management LLC purchased a new stake in Geron Corporation (NASDAQ: GERN) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor purchased 505,817 shares of the biopharmaceutical company's stock, valued at approximately $647,000. ADAR1 Capital Management LLC owned approximately 0.08% of Geron at the end
FOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective August 17, 2026, it granted stock options to purchase an aggregate of 311,250 shares of common stock to six newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
Genron Corp. reported Q2'26 net product revenues of $57.5M from U.S. sales of Rytelo, up 11% from Q1'26. GERN's management did not increase its 2026 revenue guidance, but did suggest revenues were likely to reach the mid- to high-end of that guidance. A potential competitor in myelofibrosis, KPTI, is looking to file for approval in frontline myelofibrosis, while GERN is running its phase 3 study in…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GERN.
U.S. House Trading
No House trades found for GERN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.